ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Top Cited Papers
- 30 June 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 12 (10), 573-583
- https://doi.org/10.1038/nrclinonc.2015.117
Abstract
Over the past 18 months, recurrent activating mutations within the oestrogen receptor α (ER) LBD have been detected in 15–20% of patients with metastatic ER-positive endocrine-resistant breast cancer The ER LBD mutations confer constitutive ligand-independent activity and are relatively resistant to tamoxifen and fulvestrant treatment These mutations in the gene encoding the ER, ESR1, are detected mainly in metastatic tumours, implicating the clonal selection of these mutations as the mechanism of resistance to therapy Structural studies have shown that the ER LBD mutations lead to ligand-independent stabilization of the LBD in the agonistic conformation To study the clonal evolution and discern the full genetic complexity and clinical significance of the ESR1 mutations, new sensitive sequencing technologies will need to be applied Potential strategies to overcome ER-related endocrine resistance include high-dose fulvestrant and tamoxifen, inhibitors of ER co-activator proteins, novel SERDs and SERMs, and other agents targeting the ER signalling axisKeywords
This publication has 109 references indexed in Scilit:
- Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cellsEMBO Molecular Medicine, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Acquired resistance to drugs targeting receptor tyrosine kinasesBiochemical Pharmacology, 2012
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- Clonal evolution in cancerNature, 2012
- Direct mutation analysis by high-throughput sequencing: From germline to low-abundant, somatic variantsMutation Research, 2012
- Progress in endocrine approaches to the treatment and prevention of breast cancerMaturitas, 2011
- Next-generation DNA sequencingNature Biotechnology, 2008
- NFκB selectivity of estrogen receptor ligands revealed by comparative crystallographic analysesNature Chemical Biology, 2008
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005